An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Guardant Health, Inc. (NASDAQ: GH) announced that its Guardant Reveal™ blood test for molecular residual disease (MRD) is now covered for fee-for-service Medicare patients in the US with stage II or III colorectal cancer (CRC). This coverage enables oncologists to detect circulating tumor DNA (ctDNA) in patients post-surgery, enhancing treatment decisions. The test marks a significant milestone as the first blood-only liquid biopsy for MRD testing in CRC. This decision complements existing Medicare coverage for other Guardant Health tests, boosting the company's position in precision oncology.
Positive
Guardant Reveal™ is the first blood-only liquid biopsy test covered for MRD testing in stage II or III colorectal cancer.
Coverage by Medicare enhances accessibility, likely increasing the test uptake and benefiting patient outcomes.
This coverage follows previous expansions of Medicare coverage for other Guardant Health tests, demonstrating the company's growing market presence.
Negative
None.
First blood-only liquid biopsy test for molecular residual disease testing now covered for certain fee-for-service Medicare patients in US with stage II or III colorectal cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant Reveal™ molecular residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after surgery to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy. It is the first blood-only liquid biopsy test available for MRD testing in patients with colorectal cancer (CRC).
The decision means Guardant Reveal is covered for fee-for-service Medicare patients in the United States with stage II or III CRC whose testing is initiated within three months following curative intent therapy. “We are pleased that Medicare has taken this important step to make MRD testing more widely available and help oncologists make more informed treatment decisions for their patients with colorectal cancer,” said Helmy Eltoukhy, Guardant Health co-CEO.
Medicare’s policy decision adds to the coverage of Guardant Health tests for cancer patients. In December 2019, Palmetto GBA expanded local coverage determination (LCD) of the Guardant360® assay, making it the first liquid biopsy to be broadly covered for use across the vast majority of advanced solid tumors. In March 2022, Palmetto GBA also conveyed coverage for Guardant360 TissueNext™, the company’s first tissue-based test to help oncologists identify patients with advanced cancer who may benefit from biomarker-informed treatment.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021, and any current and periodic reports filed with the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
What is the significance of Guardant Reveal™ being covered by Medicare for colorectal cancer patients?
The coverage allows Medicare patients with stage II or III colorectal cancer to access the first blood-only liquid biopsy test for detecting molecular residual disease, potentially improving treatment outcomes.
When did Medicare announce coverage for Guardant Health's blood test?
Medicare's coverage for Guardant Reveal™ was announced on the date of the press release.
What stages of colorectal cancer does the Medicare coverage for Guardant Reveal™ apply to?
The coverage applies to patients with stage II or III colorectal cancer.
How does Guardant Reveal™ help oncologists in treating colorectal cancer?
Guardant Reveal™ detects circulating tumor DNA (ctDNA) in blood post-surgery, aiding oncologists in identifying patients who may need further adjuvant therapy.
Which company is behind the Guardant Reveal™ test?
Guardant Reveal™ is developed by Guardant Health, Inc. (NASDAQ: GH).
